Roberto Solari

Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom.

Apax Partners Holdings Ltd. provides investment services. The firm focuses in the area of media, retail, health care, financial, and telecommunication sectors. The company was founded on February 6, 1991 and is headquartered in London, the United Kingdom.

Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

CalciCo Therapeutics Ltd. develops novel small molecule drugs for autoimmune and inflammatory disorders. The company was founded by Anant Parekh and is headquartered in Oxford, the United Kingdom.

Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.

Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom.